EUCTR2016-004236-38-GB进行中（未招募）1 期
OPtimising Treatment for MIld Systolic hypertension in the Elderly: a randomised controlled trial - OPTiMISE
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 540
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inclusion criteria for the main trial:
- •Participant is willing and able to give informed consent for participation in the trial.
- •Male or Female, aged 80 years or above.
- •Clinic systolic blood pressure less than 150 mmHg (according to screening measurement at baseline – clinic blood pressure defined as the mean of the 2nd and 3rd readings taken at 1 minute intervals).
- •Prescribed two or more antihypertensive medications to lower blood pressure for at least 12 months prior to trial entry. Antihypertensive medications defined as any ACE inhibitor, angiotensin II receptor blocker, calcium channel blocker, thiazide and thiazide-like diuretic, potassium-sparing diuretic, alpha-blocker or beta-blocker.
- •Stable dose of current antihypertensive medications for at least four weeks prior to trial entry.
- •In the Investigator’s opinion, could potentially benefit from medication reduction due to existing polypharmacy, co-morbidity, non-adherence or dislike of medicines and/or frailty (i.e. is different from those to which the results of the SPRINT trial are likely to apply).
- •In the Investigator’s opinion, is able and willing to comply with all trial requirements.
- •Inclusion criteria for the qualitative study 1:
- •GPs from practices within the Cambridgeshire study region
- •patients aged >80 years.
- •with controlled blood pressure (systolic blood pressure <150mmHg) (according to medical records).
- •receiving =2 antihypertensive medications.
- •no compelling indication for medication continuation.
- •GP considers may benefit from medication reduction due to existing polypharmacy, co-morbidity and frailty.
- •Inclusion criteria for the qualitative study 2:
- •Patients screened for the main trial
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range 0
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 540
排除标准
- •Exclusion criteria for the main trial:
- •A participant has heart failure due to LVSD and is on only ACE inhibitors/ARBs and/or beta-blockers and/or spironolactone (removing any of which would be contraindicated).
- •A participant has heart failure but has not had an echocardiogram since its onset (might have undiagnosed LVSD and a compelling need for ACEI/ARB and Betablockers).
- •Investigator deems that there is a compelling indication for medication continuation.
- •Suffered a myocardial infarction or stroke within the past 12 months.
- •Blood pressure being managed outside of primary care.
- •A participant with secondary hypertension.
- •A participant with previous accelerated or malignant hypertension.
- •Unable to provide consent unless a consultee is available to provide assent in cases of incapacity.
- •Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant’s ability to participate in the trial (e.g. terminal illness, house bound and unable to attend baseline and follow up clinics).
- •Participants who have participated in another research trial involving antihypertensive medication in the past 4 weeks.
- •Exclusion criteria for the qualitative study 1:
- •Capacity to consent and participate in an interview
- •Exclusion criteria for the qualitative study 2:
研究者
相似试验
进行中（未招募）
4 期
Optimising treatment for mild systolic hypertension in the elderly - long-term follow-upSpecialty: Primary Care, Primary sub-specialty: AgeingUKCRC code/ Disease: Cardiovascular/ Hypertensive diseasesCirculatory SystemHypertensionISRCTN97503221niversity of Oxford569
尚未招募
Unknown
Role of homeopathy in essential hypertensioCTRI/2023/05/052409Bakson Homoeopathic Medical College and Hospital
进行中（未招募）
1 期
Seeking the ideal anti-hypertensive therapy in obesity-related hypertension. An open-label, single center, randomized clinical trial.obesity linked hypertensionMedDRA version: 19.0Level: PTClassification code 10020772Term: HypertensionSystem Organ Class: 10047065 - Vascular disordersEUCTR2016-000571-25-ESFundació Clinic per a la Recerca Biomèdica
已完成
不适用
STEPWISE treatment of uncontrolled HyperTensioN in primary care: a cluster randomised trial.NL-OMON50648Julius Centrum240
进行中（未招募）
1 期
Optimal Treatment of Drug Resistant Hypertension - Optimal Treatment of Drug Resistant HypertensioMedDRA version: 15.0 Level: PT Classification code 10020772 Term: Hypertension System Organ Class: 10047065 - Vascular disordersHypertensionEUCTR2008-007149-30-GBCambridge University Hospitals NHS Foundation Trust and University of Cambridge346